NCT07885332Active, not recruiting
Real-World Use of Tarlatamab in Chinese Patients With Small-Cell Lung Cancer
Real-World Effectiveness and Safety of Tarlatamab as Second-Line or Later-Line Therapy in Chinese Patients With Extensive-Stage Small-Cell Lung Cancer: A Single-Center Retrospective Cohort Study
Source: ClinicalTrials.gov · Last updated 21 Oct 2026
Brief summary (registry, in English)
This is an investigator-initiated, single-center, observational, noninterventional retrospective real-world cohort study evaluating the effectiveness and safety of tarlatamab as second-line or later-line therapy in Chinese adults with extensive-stage small-cell lung cancer. Clinical data are retrospectively collected from patients who received tarlatamab as part of routine clinical care. The primary outcome is overall objective response rate (ORR). Secondary outcomes include overall disease control rate (DCR) and the incidence and severity of adverse events, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Treatment with tarlatamab and supportive management was determined independently by treating physicians and was not assigned by the study protocol.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 26 (actual)
- First submitted
- 27 Sept 2026
- Start date
- 3 Aug 2026
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- Ruijin Hospital
- Diseases
- Lung cancer
- NCT number
- NCT07885332
What you commit to
- Study type: Observational
- Participants enrolled: 26
- From 3 Aug 2026 to the primary completion date, 30 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- No documented tarlatamab exposure.
- Insufficient clinical information for evaluation of tumor response and safety outcomes.
Who the study is looking for
- Age ≥18 years.
- Pathologically confirmed extensive-stage small-cell lung cancer (ES-SCLC).
- Received tarlatamab after at least one prior systemic treatment regimen that included platinum-based chemotherapy.
- Documented exposure to tarlatamab in routine clinical practice.
- Available clinical information sufficient for evaluation of tumor response and safety outcomes.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine (Hainan Boao Research Hospital) Coordinator of this site? Confirm its status | Qionghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.